Key result
Single-session multivessel PCI was associated with a similar 5-year risk of death, myocardial infarction, or stroke compared to staged multivessel PCI (HR 0.91; 95% CI 0.72-1.16; P=0.47).
Why the study?
Does single-session multivessel PCI reduce the composite of all-cause death, myocardial infarction, and stroke compared to staged multivessel PCI in patients with stable CAD or NSTE-ACS?
Cohort (n=2,018)
Does single-session multivessel PCI reduce the composite of all-cause death, myocardial infarction, and stroke compared to staged multivessel PCI in patients with stable CAD or NSTE-ACS?
Single-session multivessel PCI yields comparable 5-year clinical outcomes to staged multivessel PCI in patients with stable CAD or NSTE-ACS, despite a higher 30-day mortality likely driven by baseline clinical status.
Supports similar long-term outcomes with single-session multivessel PCI; leaves open confirmation by randomized trials.
OBJECTIVES: To clarify the effect of single-session multivessel percutaneous coronary intervention (PCI) strategy relative to the staged multivessel strategy on clinical outcomes in patients with stable coronary artery disease (CAD) or non-ST-elevation acute coronary syndrome. METHODS: In the Coronary REvascularisation Demonstrating Outcome Study in Kyoto PCI/coronary artery bypass grafting registry cohort-2, there were 2018 patients who underwent elective multivessel PCI. Primary outcome measure was composite of all-cause death, myocardial infarction and stroke at 5-year follow-up. RESULTS: Single-session multivessel PCI and staged multivessel PCI were performed in 707 patients (35.0%) and 1311 patients (65.0%), respectively. The cumulative 5-year incidence of and adjusted risk for the primary outcome measure were not significantly different between the single-session and staged groups (26.7% vs 23.0%, p=0.45; HR 0.91, 95% CI 0.72 to 1.16, p=0.47). The 30-day incidence of all-cause death was significantly higher in the single-session group than in the staged group (1.1% vs 0.2%, p=0.009). However, the causes of death in 11 patients who died within 30 days were generally not related to the procedural complications, but related to the serious clinical status before PCI. For the subgroup analyses including age, gender, extent of CAD, severe chronic kidney disease and heart failure, there was no significant interaction between the subgroup factors and the effect of the single-session strategy relative to the staged strategy for the primary outcome measure. CONCLUSIONS: The single-session multivessel PCI strategy was associated with at least comparable 5-year clinical outcomes compared with the staged multivessel PCI, although the prevalence of the single-session strategy was low in the present study.
No takes yet. Share an insight, caveat, or question.
Toyota et al. (2017) conducted a cohort in Stable coronary artery disease (CAD) or non-ST-elevation acute coronary syndrome (n=2,018). Single-session multivessel PCI vs. Staged multivessel PCI was evaluated on Composite of all-cause death, myocardial infarction and stroke (HR 0.91, 95% CI 0.72 to 1.16, p=0.47). Single-session multivessel PCI was associated with a similar 5-year risk of death, myocardial infarction, or stroke compared to staged multivessel PCI (HR 0.91; 95% CI 0.72-1.16; P=0.47).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: